FDA Approves VYVGART — argenx US

# FDA Approves argenx's VYVGART for Myasthenia Gravis argenx US received FDA approval for VYVGART (efgartigimod alfa), a novel intravenous immunoglobulin G-degrading enzyme subcategory immunoglobulin that targets a significant unmet need in autoimmune disease treatment and positions the company to capture share in the specialized immunology market. The approval of this first-in-class therapy could establish argenx as a key player in the rare neuromuscular disease space, with potential blockbuster revenue implications